AstraZeneca PLC — Regulatory Filings 2025

Aug 26, 2025

6-K 1 a6775w.htm HOLDING(S) IN COMPANY Document created using Blueprint(R) - powered by Issuer Services - www.issuerservices.net Copyright 2025 Issuer Services a6775w

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of August 2025

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Holding(s) in Company

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB0009895292

Issuer Name

ASTRAZENECA PLC

UK or Non-UK Issuer

UK

1. Reason for Notification

An acquisition or disposal of voting rights

1. Details of person subject to the notification obligation

Name

The Capital Group Companies, Inc.

City of registered office (if applicable)

Los Angeles

Country of registered office (if applicable)

USA

1. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

1. Date on which the threshold was crossed or reached

22-Aug-2025

1. Date on which Issuer notified

25-Aug-2025

1. Total positions of person(s) subject to the notification obligation

| | %
of voting rights attached to shares (total of 8.A) | %
of voting rights through financial instruments (total of 8.B 1 +
8.B 2) | Total
of both in % (8.A + 8.B) | Total
number of voting rights held in issuer |
| --- | --- | --- | --- | --- |
| Resulting situation
on the date on which threshold was crossed or reached | 5.009701 | 0.000000 | 5.009701 | 77684561 |
| Position of
previous notification (if applicable) | 4.997854 | 0.000000 | 4.997854 | |

1. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	% of direct voting rights (DTR5.1)
GB0009895292 Common
Stock	62998778	4.062648
US0463531089
Depository Receipt	14685783	0.947053
Sub
Total 8.A	77684561	5.009701%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument
Sub
Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument
Sub
Total 8.B2

1. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking
The
Capital Group Companies, Inc.	Capital
Research and Management Company
The
Capital Group Companies, Inc.	Capital
International, Inc.
The
Capital Group Companies, Inc.	Capital
Group Private Client Services, Inc.
The
Capital Group Companies, Inc.	Capital
International Sarl
The
Capital Group Companies, Inc.	Capital
International Limited

1. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

1. Additional Information

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds, other pooled investment vehicles, as well as individual and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of six investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl, Capital International K.K., Capital Group Private Client Services Inc, and Capital Group Investment Management Private Limited. CGII management companies primarily serve as investment managers to institutional and high net worth clients. CB&T is a U.S.-based registered investment adviser and an affiliated federally chartered bank.Neither CGC nor any of its affiliates own shares of the Issuer for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

1. Date of Completion

25-Aug-2025

1. Place Of Completion

Los Angeles

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 26 August 2025

| By: /s/
Matthew Bowden |
| --- |
| Name:
Matthew Bowden |
| Title:
Company Secretary |